Issue of Equity

RNS Number : 4750B

e-Therapeutics plc

07 January 2015

 



e-Therapeutics plc

('e-Therapeutics' or 'the Company')

Issue of Equity

7 January 2015, Oxford and Newcastle, UK: e-Therapeutics plc (AIM: ETX), the drug discovery and development company, announces that Professor Oliver James, who retired as Non-Executive Chairman of the Company with effect from 31 December 2014 has been issued with 40,948 new ordinary shares in the Company ("Ordinary Shares") in part lieu of his fees for the period ended 31 December 2014.

The new Ordinary Shares were issued on 6 January 2015 at a price of 27.00 pence per share, this being the average of the closing mid-market prices for the five business days ending on the day of his retirement.

Accordingly application has been made to admit the 40,948 new Ordinary Shares to trading on AIM and dealings in the new Ordinary Shares are expected to commence on 13 January 2015. Following admission the number of Ordinary Shares in issue in the Company will be 264,362,821. This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, e-Therapeutics plc under the Financial Conduct Authority's Disclosure and Transparency Rules.

-Ends-

Contacts:

e-Therapeutics plc

Steve Medlicott

Tel: [phone]

www.etherapeutics.co.uk 

N+1 Singer LLP

Aubrey Powell / Jen Boorer

Tel: [phone]

www.n1singer.com 

Instinctif Partners

Melanie Toyne-Sewell / Emma Barlow

Tel: [phone]

Email: [e-mail]

About e-Therapeutics plc

e-Therapeutics is an AIM-quoted drug discovery and development company with a proprietary platform in network pharmacology, an innovative new approach to drug discovery based on advances in network science and chemical biology. The Company's discovery and development activity is currently focused in cancer and disorders of the nervous system.

e-Therapeutics is based at sites in Oxford and Newcastle, UK. For more information about the Company, please visit www.etherapeutics.co.uk.

 

END

 

 

IOESSMEFMFISESF